Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 14 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (4)
Early P 1 (1)
P 2 (2)
P 3 (2)

Trial Status

Completed7
Recruiting3
Not Yet Recruiting2
Unknown2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT07325903Early Phase 1Not Yet RecruitingPrimary

Research of Integrated Traditional Chinese and Western Medicine on Precocious Puberty

NCT06083415Not ApplicableRecruitingPrimary

Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context

NCT06263868RecruitingPrimary

First Observatory of Precocious Puberty.

NCT00278915Phase 2CompletedPrimary

Faslodex in McCune-Albright Syndrome

NCT04884620Recruiting

The 3rd COPENHAGEN Puberty Study

NCT05957991Not Yet RecruitingPrimary

Danish Precocious Puberty Study - DAPP Study A National Cohort Study on Incidence and Etiologies for Precocious Puberty

NCT00494169Completed

Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders

NCT03628937Not ApplicableUnknown

The Effect of Decaffeinated Green Tea Polyphenol Intake on the Risk of Precocious Puberty Among Obese Girls

NCT04012632CompletedPrimary

Kisspeptin/GPR54 Pathway and Early Puberty

NCT02431416Not ApplicableCompletedPrimary

Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty

NCT00094328Phase 2CompletedPrimary

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

NCT02790112Not ApplicableUnknownPrimary

Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty

NCT00635817Phase 3CompletedPrimary

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

NCT00660010Phase 3CompletedPrimary

Study of Lupron Depot In The Treatment of Central Precocious Puberty

Showing all 14 trials

Research Network

Activity Timeline